Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
2019 · New England Journal of Medicine · 1,275 citations
https://doi.org/10.1056/nejmoa1914609
A
Alicia Okines
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
267
Papers
12.7K
Citations
41
h-index
79
i10-index
Alicia Okines is an academic researcher from Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Genomics and Diagnostics & Advanced Breast Cancer Therapies. The author has an h-index of 41, co-authored 227 publications.
ORCID: 0000-0002-2068-2593Papers by this author
worksCOVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
2020 · The Lancet Oncology · 599 citations
https://doi.org/10.1016/s1470-2045(20)30442-3
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · The Lancet · 556 citations
https://doi.org/10.1016/s0140-6736(21)00149-5
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
2020 · Journal of Clinical Oncology · 529 citations
https://doi.org/10.1200/jco.20.00775
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · The Lancet · 516 citations
https://doi.org/10.1016/s0140-6736(21)00897-7
Mismatch Repair Deficiency, Microsatellite Instability, and Survival
2017 · JAMA Oncology · 509 citations
https://doi.org/10.1001/jamaoncol.2016.6762
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat